RNA splicing variants were found to be critical drivers of prostate cancer aggressiveness and therapeutic resistance in African American men.
Genitourinary Cancer Targets
Men with prostate cancer and one additional primary cancer may harbor a mutation in a cancer-predisposing gene, but the majority of these men do not meet criteria for clinical genetic testing.
A study may be able to identify which men with aggressive prostate cancer will benefit from androgen deprivation therapy.
In this video, David Goodrich, PhD, of Roswell Park Cancer Institute in Buffalo, discusses treatment resistance and disease relapse in prostate cancer.
Dr. Roland Seiler presented an analysis of how different bladder cancer molecular subtypes respond to neoadjuvant chemotherapy at the 2017 ASCO Genitourinary Cancer Symposium.
Ahead of the ASCO-sponsored 2017 Genitourinary Cancers Symposium being held February 16th to February 18th in Orlando, Florida, we spoke with Dr. Ana Aparicio about the role of androgen receptors in prostate cancer.
We spoke with Dr. Monika Joshi on the use of radiation therapy and durvalumab in patients with locally advanced bladder cancer.
A new study is suggesting that by targeting a specific microRNA molecule (miR-141) it may be possible to stop the cascade of events that lead to metastasis in men with prostate cancer.
A new German multicenter study is suggesting that lutetium-177 (Lu-177)-labeled PSMA-617 may be a promising new therapeutic agent for radioligand therapy in men with metastatic castration-resistant prostate cancer.
A new study is suggesting it may be possible to shut down the circuits that drive the high tumorigenicity of prostate cancer cells leading to castration-resistant prostate cancer.